Cargando…

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 studies as an oral extended-release (ER) formulation administered once daily. The purpose of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Mohamed-Eslam F., Trueman, Sheryl, Othman, Ahmed A., Han, Jian-Hwa, Ju, Tzuchi R., Marroum, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814631/ https://www.ncbi.nlm.nih.gov/pubmed/31654328 http://dx.doi.org/10.1208/s12248-019-0378-y

Ejemplares similares

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2019)

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
por: Mukherjee, Dwaipayan, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
por: Kadivar, Ali, et al.
Publicado: (2015)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Formulation and in vitro Evaluation of Alfuzosin Extended Release Tablets Using Directly Compressible Eudragit
por: Roni, M. A., et al.
Publicado: (2009)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Formulation of Modified-Release Bilayer Tablets of Atorvastatin and Ezetimibe: An In-Vitro and In-Vivo Analysis
por: Mubeen, Iqra, et al.
Publicado: (2022)

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
por: Badawi, Mohamed, et al.
Publicado: (2022)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
por: Oliveira, Paulo Renato, et al.
Publicado: (2013)

Proniosomal Telmisartan Tablets: Formulation, in vitro Evaluation and in vivo Comparative Pharmacokinetic Study in Rabbits
por: Teaima, Mahmoud Hasan, et al.
Publicado: (2020)

Development and validation of an in vitro–in vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations
por: Cheng, Chinhwa, et al.
Publicado: (2013)

Development and In Vitro–In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease
por: Zhang, Chi, et al.
Publicado: (2023)

Formulation and Evaluation of Trimetazidine Dihydrochloride Extended Release Tablets by Melt Congealing Method
por: Javeer, S. D., et al.
Publicado: (2010)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

In Vitro-In Vivo Correlation Evaluation of Generic Alfuzosin Modified Release Tablets
por: Sanki, Utpal Kumar, et al.
Publicado: (2012)

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
Publicado: (2022)

In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine
por: Incecayir, Tuba, et al.
Publicado: (2023)

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2017)

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
por: Ponce-Bobadilla, Ana Victoria, et al.
Publicado: (2022)

Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
por: Pardo, Antonio, et al.
Publicado: (2021)

In Vitro–In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets
por: Lee, Ye-Ji, et al.
Publicado: (2022)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies
por: Al Zahabi, Khaled H., et al.
Publicado: (2021)

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
por: Parmentier, Julie M., et al.
Publicado: (2018)

Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
por: Jishnu, V, et al.
Publicado: (2011)

Design and evaluation of an extended-release matrix tablet formulation; the combination of hypromellose acetate succinate and hydroxypropylcellulose
por: Fukui, Sachiko, et al.
Publicado: (2017)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bc8jh05f7jrp9di6v6k1a0slfj